Amyloidosis is a rare disease that involves the buildup of a specific protein called amyloid. Unlike other proteins, amyloid does not have a supportive role in the body. Instead, the buildup of ...

How Nuclear Cardiology Transformed Patient Care in Cardiac Amyloidosis, and What the Remarkable Developments in the Field Have Taught Us Developments have unfolded in cardiac amyloidosis, ... where we ...

Interviewer: Amyloidosis is a rare and possibly debilitating disease, which affects about 4,000 people a year in the United States. If left untreated, the disease can cause severe organ damage, so ...

The new understanding of molecular events that drive the various forms of amyloidosis has led to the expansion of therapeutic options to prevent end-stage disease or even offer a cure, which has added ...

Care of patients with systemic immunoglobulin light chain (AL) amyloidosis has undergone transformative changes, leading to marked, steady progress in outcomes for patients over the past four decades.

It is possible for transthyretin amyloid cardiomyopathy (ATTR-CM, also called cardiac ATTR amyloidosis) to be reversed with antibody treatment, as suggested by rare cases of patients who had their ...

When Sally Cox was diagnosed with light chain amyloidosis (AL) in 2019, she was shocked. Not only had she never heard of the rare disease that causes abnormal proteins (or amyloids) to build up in ...

MSK cellular therapist Dr. Heather Landau led a phase 1 clinical trial showing CAR T cell therapy is effective against relapsed or resistant AL amyloidosis. “I’ve seen very sick patients have an ...

Amyloid heart disease occurs when amyloid fibrils build up in the heart, making it more difficult for the heart to pump blood around the body. Eventually, this can lead to heart failure. People can ...